Advertisements



We are Sorry, This Page doesn't Exist


Crispr stock up 8% as company says FDA accepted new-drug application

Shares of Crispr Therapeutics AG rose mo.....»»

Category: topSource: marketwatchOct 10th, 2018

FDA PDUFA Date for Insmed New Drug Application for ALIS is September 28, 2018

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 28th, 2018

Generic drug giant eyes consolidation at Rechler warehouse space

The Town of Brookhaven Industrial Development Agency (IDA) has accepted an economic incentives application from Amneal Pharmaceuticals that will allow the drug maker to lease 84,000 s/f of warehou.....»»

Category: realestateSource: realestateweeklySep 20th, 2018

Bristol-Myers" MM Drug Empliciti Application Validated by EMA

Zacks.....»»

Category: topSource: redinewsSep 20th, 2018

Bristol-Myers" MM Drug Empliciti Application Validated by EMA

Bristol-Myers' (BMY.....»»

Category: worldSource: nytSep 19th, 2018

Tilray stock rises 29% on plans to import cannabis to U.S. for clinical trial

The U.S. Drug Enforcement Administration has signed off on cannabis cultivator Tilray Inc.’s plan to import a pot product from Canada to test a pot pill’s effectiveness at treating a disorder that affects millions of Americans......»»

Category: topSource: marketwatchSep 18th, 2018

Tilray stock rises 10% on plans to import cannabis to US for clinical trial - MarketWatch

Charlotte ObserverTilray stock rises 10% on plans to import cannabis to US for clinical trialMarketWatchThe U.S. Drug Enforcement Administratio.....»»

Category: topSource: googlenewsSep 18th, 2018

Tilray stock rises 10% on plans to import cannabis to U.S. for clinical trial

The U.S. Drug Enforcement Administration has signed off on cannabis cultivator Tilray Inc.’s plan to import a pot product from Canada to test a pot pill’s effectiveness at treating a disorder that affects millions of Americans......»»

Category: topSource: marketwatchSep 18th, 2018

Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection. GlaxoSmi.....»»

Category: personnelSource: nytSep 17th, 2018

Can Acorda Therapeutics Get Past This FDA Move?

Acorda Therapeutics shares dipped on Thursday after the company announced that the FDA would be delaying its Prescription Drug User Fee Act goal date for its review of the New Drug Application of........»»

Category: blogSource: 247wallstSep 13th, 2018

Mid-Morning Market Update: Markets Mixed; Foamix Acne Drug Trial Meets Endpoints

Following the market opening Wednesday, the Dow traded up 0.17 percent to 26,014.06 while the NASDAQ declined 0.57 percent to 7,926.67. The S&P also fell, dropping 0.07 percent to 2,885.98. read more.....»»

Category: blogSource: benzingaSep 12th, 2018

Bausch Health"s New Drug Application for Duobrii accepted by FDA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 29th, 2018

Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis

Amgen (AMGN) submits a supplemental new drug application to the FDA, seeking an approval for once-weekly dosage of its multipl.....»»

Category: smallbizSource: nytAug 28th, 2018

AbbVie"s Rare Blood Cancer Drug Combo Snags FDA Approval

AbbVie Inc (NYSE: ABBV) has received FDA approval of its supplemental New Drug Application for Imbruvica to treat a rare type of cancer. read more.....»»

Category: blogSource: benzingaAug 27th, 2018

Mallinckrodt confirms FDA has rejected a treatment for babies at risk of developing jaundice

Drug company Mallinckrodt Plc confirmed Wednesday that the U.S. Food and Drug Administration has rejected its new drug application fo.....»»

Category: topSource: marketwatchAug 22nd, 2018

Nymox" Removal Of Its Marketing Application Suggests That The Company Believes Its Drug Will Be Rejected

Nymox" Removal Of Its Marketing Application Suggests That The Company Believes Its Drug Will Be Rejected.....»»

Category: topSource: seekingalphaAug 15th, 2018

FDA clears digital contraceptive "Natural Cycles" to be marketed in U.S.

Natural Cycles, a mobile phone application that can be used to prevent pregnancy, was cleared by the Food and Drug Administration o.....»»

Category: topSource: marketwatchAug 10th, 2018

FDA Decision Sends Pain Therapeutics Reeling

Pain Therapeutics, Inc. (NASDAQ: PTIE) plunged 47.7 percent Monday after receiving a Complete Response Letter from the Food and Drug Administration for Remoxy’s New Drug Application. read more.....»»

Category: blogSource: benzingaAug 6th, 2018

FDA Decision Sends Pain Therapeutics, Durect Corp. Reeling

Pain Therapeutics, Inc. (NASDAQ: PTIE) plunged 47.7 percent Monday after receiving a Complete Response Letter from the Food and Drug Administration for Remoxy’s New Drug Application. read more.....»»

Category: blogSource: benzingaAug 6th, 2018

Mortgage Fraud Risk Rises for Seventh Straight Quarter

Real-estate information researchers at CoreLogic reported Thursday that the risk to mortgage lenders of a fraudulent application rose 12% year over year in the second quarter of 2018, the seventh........»»

Category: blogSource: 247wallstJul 19th, 2018